Fig. 3: ctDNA-based MRD testing is predictive of response to ACT in postsurgical patients with CRC.
From: Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
a,b, Kaplan–Meier estimates for DFS stratified by observation and ACT in patients with high-risk pathological stage II or stage III disease and ctDNA positivity 4 weeks after surgery (a) (HR was adjusted by sex and performance status) and ctDNA negativity 4 weeks after surgery (b) (HR was adjusted by age, pathological stage, MSI and performance status). HRs and 95% CIs were calculated using the Cox proportional hazard model. P values were calculated using the two-sided log-rank test.
